Zinforo

RSS

ceftaroline fosamil

Authorised
This medicine is authorised for use in the European Union.

Overview

Zinforo is an antibiotic. It is used to treat adults and children (including newborn babies) who have:

  • complicated infections of the skin and soft tissue (tissue below the skin). ‘Complicated’ means that the infection is difficult to treat;
  • community-acquired pneumonia (an infection of the lungs that is caught outside of hospital).

Prescribers should consider official guidance on the appropriate use of antibiotics.

Zinforo contains the active substance ceftaroline fosamil.

This EPAR was last updated on 17/10/2019

Authorisation details

Product details
Name
Zinforo
Agency product number
EMEA/H/C/002252
Active substance
Ceftaroline fosamil
International non-proprietary name (INN) or common name
ceftaroline fosamil
Therapeutic area (MeSH)
  • Community-Acquired Infections
  • Skin Diseases, Infectious
  • Pneumonia
Anatomical therapeutic chemical (ATC) code
J01DI02
Publication details
Marketing-authorisation holder
Pfizer Ireland Pharmaceuticals
Revision
21
Date of issue of marketing authorisation valid throughout the European Union
22/08/2012
Contact address
Operations Services Group
Ringaskiddy
County Cork
Ireland

Product information

25/07/2019 Zinforo - EMEA/H/C/002252 - II/0041

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults:

  • Complicated skin and soft tissue infections (cSSTI)
  • Community-acquired pneumonia (CAP)

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating